Immupharma PLC Interim Board Change (2760M)
May 06 2015 - 2:02AM
UK Regulatory
TIDMIMM
RNS Number : 2760M
Immupharma PLC
06 May 2015
6 May 2015
INTERIM BOARD CHANGE
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces that
Dr Franco Di Muzio, senior Non-Executive Director will take on the
role of Chairman on an interim basis. Due to recent ill health,
Richard Warr, Executive Chairman, has taken a leave of absence in
order to make a full recovery.
Commenting on the announcement, Dr Franco Di Muzio said:"As the
Senior Non-Executive Director of ImmuPharma since its formation, I
have an in-depth knowledge of the Company and would like to assure
shareholders of my commitment to fulfilling the responsibilities
required in the position of Interim Chairman during this period.
The Board would like to wish Richard a speedy recovery."
- Ends -
For further information please contact:
+ 44 (0) 20
ImmuPharma plc 7152 4080
Dimitri Dimitriou, Chief Executive
Officer
Lisa Baderoon, Head of Investor + 44 (0) 7721
Relations 413496
Panmure, Gordon & Co., NOMAD & +44 (0) 20 7886
Broker 2500
Hugh Morgan, Fred Walsh, Duncan
Monteith (Corporate Finance)
Charles Leigh-Pemberton (Corporate
Broking)
Notes to Editors:
Dr Franco Di Muzio, Senior Non-Executive Director
Dr Di Muzio has 40 years' experience in the pharmaceutical and
other industries, encompassing international management experience
in business development, strategic marketing, international
finance, M & A and re-engineering businesses. After graduating
in Economics and Business in 1963, Dr Di Muzio worked for Colgate
Palmolive and Nestle before joining Squibb (now Bristol Myers
Squibb) for eight years. Dr Di Muzio became Executive Vice
President of BMS' medical equipment and products division, Weck
International Inc., in charge of Europe, Asia, Middle East and
Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline
plc) in London as Area Managing Director and Head of all GW's
business in the Middle East, Africa and Turkey. Following early
retirement from Glaxo Wellcome, in the beginning of 1998, he joined
Alza International, the then world leader in drug delivery systems,
as Managing Director, based in London, in charge of the company's
business expansion in all markets outside the US and remained there
until the end of 2000.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFLAEVIEIIE
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024